Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6055297 | Oral Oncology | 2011 | 5 Pages |
Abstract
Celebrex and radiotherapy in advanced head and neck cancer. This phase I dose-escalation study seeks to determine the phase II recommended dose of cyclooxygenase type 2 (COX-2) inhibitor in patients with locally advanced squamous cell head and neck (H&N) cancer, treated with accelerated radiotherapy. Anti-vasculogenic effect of this treatment on serum vascular endothelial growth factor (VEGF) is examined. Patients were irradiated with curative intent (72 Gy in 6 weeks). Celecoxib was administered throughout the radiotherapy course. Serum VEGF level were tested during radiotherapy and in follow-up. Tumor specimens were stained to quantify the COX-2 expression. Thirty-two patients completed the treatment. The dose of celecoxib was escalated (200, 400 and 800 mg bid, then de-escalated to 600 mg bid). The acute toxicity related to the treatment in the first and second cohort did not reach grade III; in the third cohort three patients had grade III radiation toxicity and one had celecoxib-related toxicity. In the last fourth cohort the toxicity was acceptable. Significant VEGF level drop (p = 0.011) was found between radiation day 1 and post-treatment visit. Significant decrease (p = 0.022) of the VEGF level was shown in patients with high COX-2 expression in the tumor. Phase II recommended dose of celecoxib combined with accelerated radiotherapy in advanced H&N cancer was 600 mg bid. A significant decrease of the post-treatment serum VEGF level compared to the initial level was noticed only in patients with high COX-2 expression in tumors.
Keywords
ICRUGTVIMRTCTVPTVCOX-2 expressionGross target volumeDVHCOX-2RTOGELISAEnzyme-linked immunosorbent assayClinical target volumeGrayRadiotherapyHead and neckHead and neck cancerCelecoxibVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Dose-volume histogramintensity-modulated radiation therapyBIDRadiation Therapy Oncology Group
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Magdalena Halamka, Jakub Cvek, Jiri Kubes, Eva Zavadova, Pavel Kominek, Jaroslav Horacek, Ladislav Dusek, David Feltl,